WallStSmart

Guardian Pharmacy Services, Inc. (GRDN)vsUniversal Health Services Inc (UHS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Universal Health Services Inc generates 1120% more annual revenue ($17.76B vs $1.46B). UHS leads profitability with a 8.6% profit margin vs 3.6%. UHS trades at a lower P/E of 6.1x. UHS earns a higher WallStSmart Score of 70/100 (B).

GRDN

Hold

50

out of 100

Grade: D+

Growth: 7.3Profit: 6.5Value: 4.0Quality: 7.0
Piotroski: 3/9Altman Z: 5.30

UHS

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 7.0Value: 6.0Quality: 6.0
Piotroski: 5/9Altman Z: 2.76
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for GRDN.

UHSSignificantly Overvalued (-29.7%)

Margin of Safety

-29.7%

Fair Value

$178.30

Current Price

$145.17

$33.13 premium

UndervaluedFair: $178.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GRDN4 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
5.3010/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
24.0%9/10

Every $100 of equity generates 24 in profit

Debt/EquityHealth
0.179/10

Conservative balance sheet, low leverage

EPS GrowthGrowth
39.0%8/10

Earnings expanding 39.0% YoY

UHS3 strengths · Avg: 9.7/10
P/E RatioValuation
6.1x10/10

Attractively priced relative to earnings

Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Return on EquityProfitability
20.2%9/10

Every $100 of equity generates 20 in profit

Areas to Watch

GRDN4 concerns · Avg: 3.5/10
Price/BookValuation
11.6x4/10

Trading at 11.6x book value

Revenue GrowthGrowth
2.2%4/10

2.2% revenue growth

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

UHS0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : GRDN

The strongest argument for GRDN centers on Altman Z-Score, Return on Equity, Debt/Equity.

Bull Case : UHS

The strongest argument for UHS centers on P/E Ratio, Price/Book, Return on Equity. PEG of 1.02 suggests the stock is reasonably priced for its growth.

Bear Case : GRDN

The primary concerns for GRDN are Price/Book, Revenue Growth, Profit Margin. A P/E of 51.3x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.

Bear Case : UHS

No major red flags identified for UHS, but monitor valuation.

Key Dynamics to Monitor

UHS is growing revenue faster at 9.6% — sustainability is the question.

UHS generates stronger free cash flow (184M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

UHS scores higher overall (70/100 vs 50/100). Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Guardian Pharmacy Services, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Guardian Pharmacy Services, Inc. is a leading provider of specialized pharmacy solutions focused on the long-term care sector, serving assisted living and skilled nursing facilities. The company is recognized for its commitment to personalized medication management, high standards of quality and compliance, and superior customer service. By utilizing advanced technology and deep pharmaceutical expertise, Guardian not only improves patient outcomes but also streamlines operations for healthcare partners. With a substantial operational presence in multiple states, Guardian is well-equipped to address the growing demand for tailored pharmacy services in a rapidly evolving healthcare environment.

Universal Health Services Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

UnitedHealth Group Incorporated is an American for-profit multinational managed healthcare and insurance company based in Minnetonka, Minnesota. It offers health care products and insurance services.

Visit Website →

Want to dig deeper into these stocks?